To that matter, some potential molecules such as GLP-1 receptor agonists, used to treat T2D, or other molecules have yet to be further studied in order to judge their efficiency on NAFLD/NASH. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.